Basel, Switzerland. March 5, 2024, 9am CET
BioVersys and GSK successfully complete IMI2 programme reaching clinical milestone
BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria, announced today that in partnership with GSK they have successfully completed the Innovative Medicines Initiative (IMI2) funded programme, TRIC-TB, and reached a key milestone of delivering a Phase 2-ready tuberculosis clinical candidate, alpibectir.
The achievements of TRIC-TB an EU public private partnership program have been highlighted in a TRIC-TB newsletter released today by the IMI2’s Antimicrobial Resistance (AMR) Accelerator Programme. For more details, please visit here.
Dr. Marc Gitzinger, Chief Executive Officer and founder of BioVersys: “The completion of the TRIC-TB public private partnership program and successful delivery through early clinical development of a new anti-TB molecule is a great achievement. The TRIC-TB project was designed and conducted with only two partners and as such a role model for a lean and efficiently run programme between BioVersys and GSK. We are extremely grateful for the trust bestowed upon us by the European Union’s IMI2 programme and the funding that BioVersys has received that has enabled the translation of this exciting new TB treatment paradigm that is currently being investigated in Phase 2a in patients.”
Dr. Niklas Blomberg, Executive Director, Innovative Health Initiative (IHI): “Tuberculosis poses a serious threat to public health worldwide, yet developing new treatments is highly challenging. The success of TRIC-TB in advancing a novel approach to tackling TB demonstrates how public-private partnerships can make a difference in even the toughest areas of health R&D.”
Dr. David Barros-Aguirre, VP and Head of Global Health Medicines R&D Unit, Global Health R&D, GSK: “Every year, 10 million people fall ill with TB and challenges such as increasing resistance to current treatments are hindering efforts to reduce that number. New treatment regimens are much needed, so we’re really pleased that the TRIC-TB program has been completed, signifying progress towards meeting that goal. Partnerships are vital for TB research and development, and the partnership between BioVersys and GSK on this European Union IMI2 programme is a great example of what can be achieved when we work together to get ahead of TB.”
The TRIC-TB Project has received funding from the EU IMI-JU2 programme under the AMR Accelerator umbrella.
Full PR available here